Table 1 Social, demographic and clinical characteristics of the patients included in the study (mean age ± standard deviation).
From: The need for comprehensive sleep disturbances assessment and management in breast cancer care
Variable | Categories | N (%)/M ± SD |
|---|---|---|
Age | 53.31 ± 10.83 | |
Marital status | Married | 178 (72.7) |
Single | 25 (10.2) | |
Divorced | 19 (7.7) | |
Widowed | 23 (9.4) | |
Education level | No studies | 20 (8.2) |
Elementary school | 66 (26.9) | |
Middle school | 34 (13.9) | |
High school | 58 (23.7) | |
Higher education | 67 (27.3) | |
Employment situation | Currently in employment | 26 (10.6) |
Temporary sick leave | 108 (44.1) | |
Permanent sick leave | 19 (7.8) | |
Unemployed | 50 (20.4) | |
Retired | 42 (17.1) | |
BMI | 25.87 ± 5.15 | |
Underweight (< 18.5) | 9 (3.7) | |
Normal weight (18.5–24.9) | 109 44.5) | |
Overweight grade I (25.0-26.9) | 31 (12.7) | |
Overweight grade II (pre-obese) (27.0-29.9) | 44 (18) | |
Obesity type I (30.0-34.9) | 37 (15.1) | |
Obesity type II (35,0-39.9) | 8 (3.3) | |
Obesity type III (morbid) (40.0-49.9) | 4 (1.6) | |
Obesity type IV (extreme) (≥ 50) | 3 (1.2) | |
Comorbidity | Yes | 154 (62.9) |
No | 91 (37.1) | |
Family history of BC | Yes | 93 (38) |
No | 152 (62) | |
Tumor staging | 0 | 10 (4.1) |
I | 70 (28.6) | |
II | 90 (36.7) | |
III | 45 (18.4) | |
IV | 30 (12.2) | |
Grade | 1 | 34 (17) |
2 | 57 (28.5) | |
3 | 109 (54.5) | |
Estrogen receptors | Yes | 195 (79.6) |
No | 50 (20.4) | |
Progesterone receptors | Yes | 145 (59.2) |
No | 100 (40.8) | |
Molecular subtype | Luminal A/ Luminal B HER2 negative-like | 126 (51.4) |
Luminal B HER2 positive-like/HER2-type | 93 (38) | |
Triple negative | 26 (10.6) | |
Breast | Left | 133 (54.3) |
Right | 93 (38) | |
Both | 19 (7.8) | |
Current situation | Initial treatment | 179 (73.1) |
Relapse | 43 (17.6) | |
Under review | 23 (9.4) | |
Therapy | Neoadjuvant | 46 (18.8) |
Adjuvant | 199 (81.2) | |
Menopause | Natural | 103 (43.3) |
Drug-induced menopause | 69 (28.4) | |
Intervention-induced menopause | 14 (5.7) | |
Reproductive stage | 56 (22.9) | |
Treatment | Surgery | 184 (75.1) |
Chemotherapy | 209 (85.3) | |
Radiotherapy | 105 (42.9) | |
Hormonotherapy | 84 (34.3) | |
Immunotherapy | 53 (21.6) | |
Treatment combinations | Chemotherapy | 33 (13.4) |
Surgery | 8 (3.3%) | |
Surgery and chemotherapy | 44 (18) | |
Other combinations | 160 (65.3) | |
Surgical treatment | Conservative surgery | 121 (49.4) |
Uni- or bilateral mastectomy | 63 (25.7) | |
Without surgical treatment | 61 (24.9) | |
Chemotherapy cycles | Chemotherapy cycles < 4 | 146 (59.6) |
Chemotherapy cycles ≥ 4 | 99 (40.4) |
